ABSTRACT
Background: The novel COVID-19 outbreak spread rapidly around the world. Cancer patients (pts) consist of a highly vulnerable group due to underlying malignancy and/or treatment-induced immunosuppression. A high mortality rate from COVID-19 in cancer pts was previously reported. France is the fourth most affected country, with more than 150,000 infected individuals and over 28,000 deaths. GCO-002 CACOVID-19 study is a large French nationwide cohort of COVID-19 pts with solid tumors with the aim to identify risk factors of COVID-19 severity and evaluate impact on cancer treatment. Methods: Bispective multicenter cohort set up by the French Cooperative Groups in solid cancers: ANOCEF-IGCNO (CNS tumors), ARCAGY-GINECO (gynecological and breast cancers), FFCD (digestive cancers), GERCOR (digestive and other solid cancers), GORTEC/intergroupe ORL (head and neck cancers (H&N), and IFCT (thoracic cancers). French pts with solid cancers and COVID-19 diagnosed since 1 March 2020 were accrued. Exclusion criteria: pts treated curatively > 5 years ago. Results: From 6 April to 15 May 2020, 835 pts from 136 institutions (general hospitals 35%, university hospitals 35%, private centers 25%, cancer centers 5%) were registered. Men: 61%, median age: 69 years (20-100). Digestive cancers: 43% (16%/9% colorectal/pancreatic cancers), lung cancers: 22%, gynecological: 14%, (9% breast cancers), H&N: 10%, CNS: 4%, urologic cancers: 3%. Advanced or metastatic: 61%. Within 3 months before COVID-19 diagnosis, 69% of pts received a systemic anticancer treatment (chemotherapy, targeted or immune therapy) and 22% a local therapy (surgery, radiotherapy or local destruction). Diagnosis of COVID-19 was confirmed by RT-PCR, CT-scan or both in 91% or serology in 1.4%. COVID was treated in the same oncological center in 78%. During the follow-up period (mean 14 days), 208 (25%) pts died, including 173 (21%) COVID-19 related deaths. Conclusions: This first nationwide study of cancer pts with COVID-19 from France reports a high mortality rate. Updated and detailed data on anti-cancer treatments, risk factors of severe and fatal COVID-19 and impact of COVID-19 on cancer management will be presented. Legal entity responsible for the study: Fédération Francophone de Cancérologie Digestive. Funding: Has not received any funding. Disclosure: A. Lièvre: Honoraria (self), Advisory/Consultancy: AAA;Amgen, Pierre Fabre;Sandoz;Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Bayer;Novartis;Honoraria (self): Celgene;HalioDx;Lilly;Honoraria (self), Travel/Accommodation/Expenses: BMS;Roche;Honoraria (self), Research grant/Funding (self): Incyte;Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen;Merck;Servier;Research grant/Funding (self): Integragen;Travel/Accommodation/Expenses: AAA;Pfizer. A. Turpin: Honoraria (self): Servier;Advisory/Consultancy: Mylan;Merck Serono;Amgen;Travel/Accommodation/Expenses: Merck;Sanofi;Pfizer;AstraZeneca. I.L. Ray-Coquard: Honoraria (self), Advisory/Consultancy: Abbvie;Agenus;Advaxis;Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): BMS;MSD;Honoraria (self), Advisory/Consultancy: PharmaMar;Genmab;Pfizer;Deciphera;Mersena;Amgen;Tesaro;Clovis;Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck Serono;Novartis;Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca;Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche;Honoraria (self), Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: GSK;Non-remunerated activity/ies: GINECO;ENGOT;GCIG;European community;ESMO;ASCO;ESGO;IGSC;Inca;Swiss and German Health Authorities;Italian Health Authority;Belgium Health Authority. J. Thariat: Honoraria (self): BMS;Honoraria (institution), Travel/Accommodation/Expenses, Full/Part-time employment: Centre François Baclesse;Leadership role: President of the French Head and Neck Intergroup, GORTEC secretary;Non-remunerated activity/ies: Director of Easy-CRF society;Research grant/Funding (institution): Nanobiotix. G. Ahle: Travel/Accommodation/Expenses: Abbvie;Biogen;Novartis;Roche;Sanofi;Non-remunerated activity/ies: ANOCEF;NENO;AlSacEP. R. Mathieu: Honoraria (self), Research grant/Funding (self): Astellas;Honoraria (self): AstraZeneca;Ferring;Ipsen;Janssen;MSD;Pfizer;Sanofi;Takeda. D. Debieuvre: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer;Roche;Novartis;BMS;MSD;Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca;Honoraria (self), Research grant/Funding (institution): Chugaï;Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Boerhinger-Ingelheim;Research grant/Funding (institution): Chiesi;Sandoz;Takeda;GSK;Research grant/Funding (self): Lilly. A. Canellas: Honoraria (self), Advisory/Consultancy: BMS;Honoraria (self), Travel/Accommodation/Expenses: AstraZeneca;Travel/Accommodation/Expenses: Oxyvie;LVL Medical;Boerhinger Ingelheim. A-C. Hardy-Bessard: Advisory/Consultancy: Clovis;Novartis;Roche;MSD;AstraZeneca;GSK. L. Mansi: Honoraria (institution), Advisory/Consultancy: Sandoz;Advisory/Consultancy: Roche;Eisai;Pfizer;Novartis;Speaker Bureau/Expert testimony: Exact Sciences;Travel/Accommodation/Expenses: Lilly. P. Gorphe: Honoraria (self): Intuitive Surgical;Non-remunerated activity/ies: Chair, scientific board, French Head and Neck Intergroup;Research grant/Funding (institution): MSD. A. IDBAIH Ahmed: Research grant/Funding (institution): Transgene;Sanofi;Air Liquide;Travel/Accommodation/Expenses: Carthera;Leo Pharma. G. Zalcman: Honoraria (self), Honoraria (institution), Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS;Honoraria (self), Honoraria (institution), Travel/Accommodation/Expenses: AstraZeneca;Honoraria (institution), Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche;Honoraria (institution): Takeda;Travel/Accommodation/Expenses: Pfizer;AbbVie;MSD. O. Bouche: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche;Honoraria (self), Advisory/Consultancy: Merck KgaA;Bayer;AstraZeneca;Grunenthal;MSD;Honoraria (self), Speaker Bureau/Expert testimony: Amgen;Pierre Fabre;Honoraria (self), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Servier. All other authors have declared no conflicts of interest.